Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Conference attendance

1 Mar 2018 07:00

RNS Number : 3044G
Collagen Solutions PLC
01 March 2018
 

 

1 March 2018

Collagen Solutions to Present at Canaccord Genuity Musculoskeletal Conference &

Exhibit at American Academy of Orthopaedic Surgeons Conference

Dates: 6-9 March 2018

 

 

Collagen Solutions Plc (AIM: COS), (the "Company"), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine, including orthopaedic, dental, wound care, and cardiovascular applications, confirms two forthcoming conferences it will be attending in New Orleans, Louisiana, USA, between 6-9 March 2018.

· Jamal Rushdy, CEO, to present at the Canaccord Genuity Musculoskeletal Conference (6 March)· Company to Exhibit at the American Academy of Orthopaedic Surgeons "AAOS" Annual Conference (7-9 March)

 

AAOS is the world's largest and most prestigious annual orthopaedic meeting so attending this conference and presenting at the accompanying Canaccord Genuity Musculoskeletal Conference provides access to an extremely wide range of investors and manufacturers in areas of spine, trauma/extremities, foot and ankle, and sports medicine.

 

Commenting on the conferences, Jamal Rushdy, CEO said: "We are pleased to have the opportunity to present at the Canaccord Genuity Musculoskeletal Conference, where we will highlight our recently announced positive 8-year follow-on data from ChondroMimetic® demonstrating durable cartilage regeneration in keyhole knee surgery. We are also excited to be a first-time exhibitor at AAOS and to showcase our OEM capabilities and propriety device licensing opportunities to investors and industry partners. These meetings provide the opportunity to actively engage with orthopaedic companies on a global scale. We will also be providing hands-on demonstrations of prototypes for our Bone Graft Substitute, ChondroMimetic® Cartilage Repair Scaffold, and Fibrillar Collagen development programmes."

 

 

 

Collagen Solutions PlcJamal Rushdy, Chief Executive OfficerHilary Spence, Chief Financial OfficerLisa Baderoon, Head of Investor Relations

Tel: +44 (0) 141 648 9100Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com

Cenkos Securities plc (NOMAD and Broker)Stephen KeysSteve Cox

Tel: +44 (0) 207 397 8900

Walbrook PRAnna DunphyHelen Cresswell

Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.comMob: +44 (0) 7876 741 001

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com

The American Academy of Orthopedic Surgeons (AAOS)

AAOS is an orthopedic organisation. Founded at Northwestern University in 1933, as of 2015 AAOS had grown to include about 39,000 members. The group provides education and practice management services for orthopedic surgeons and allied health professionals. The AAOS also lobbies and works on public education. The AAOS describes itself as "the world's largest medical association of musculoskeletal specialists.

For more information go to: www.aaos.org

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAZMGZZNRFGRZM
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.